Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study) - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue British Journal of Dermatology Année : 2024

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)

Sofia Tzoumpa
Olivier Dereure
  • Fonction : Auteur
Raphaël Janela-Lapert
  • Fonction : Auteur

Résumé

The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.
No abstract available
Fichier non déposé

Dates et versions

inserm-04559196 , version 1 (25-04-2024)

Identifiants

Citer

Sofia Tzoumpa, Saskia Ingen-Housz-Oro, Adèle de Masson, Anne Pham-Ledard, Tarik El Aarbaoui, et al.. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study). British Journal of Dermatology, 2024, pp.ljae153. ⟨10.1093/bjd/ljae153⟩. ⟨inserm-04559196⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More